^
    Back
    Association details:
    Biomarker:GNAQ mutation
    Cancer:Uveal Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

    Excerpt:
    ...- Histologically or cytologically confirmed diagnosis of metastatic uveal melanoma or previously documented mutation-positive GNAQ or GNA11 metastatic melanoma...
    Trial ID:
    NCT01328106
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Lancet Oncol
    Title:

    Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial

    Excerpt:
    Among the 16 patients with uveal melanoma, two patients (13%) achieved a 24% tumour reduction, one of whom was GNAQ mutation-positive and received study treatment for >16 weeks (Figures 1E and 1F; Table 3)
    DOI:
    10.1016/S1470-2045(12)70269-3